Arcutis Biotherapeutics, Inc. (ARQT) Stock Price & Analysis
Arcutis Biotherapeutics, Inc. (ARQT) rose 5.80% to USD 22.79 as of June 10, 2026 at 02:14 UTC, according to Nexqual real-time market data.
ARQT last closed at USD 21.54; the session ranged USD 21.72–22.87 on volume of 1,743,298 shares. Market capitalization is $2.85B, with a 52-week range of USD 12.72–31.77 (NMS). Source: Nexqual, June 10, 2026 at 02:14 UTC.
Key Statistics (as of June 10, 2026 at 02:14 UTC)
| Price | USD 22.79 |
|---|---|
| Change | ▲ 5.80% (up) |
| Previous Close | USD 21.54 |
| Open | USD 21.9 |
| Day Range | USD 21.72 – 22.87 |
| 52-Week Range | USD 12.72 – 31.77 |
| Volume | 1,743,298 shares |
| Market Cap | $2.85B |
| Exchange | NMS |
Technical Analysis (ARQT)
Nexqual's technical model rates ARQT "NEUTRAL" based on 4 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 02:14 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 56.36 (neutral) |
| vs SMA50 | Above (USD 22.53) |
| MACD | -0.14 (negative) |
Analyst Ratings (ARQT)
Wall Street analysts rate ARQT "Strong Buy" based on 8 analysts, with a mean price target of USD 34.63 (range USD 33–36), per Nexqual as of June 10, 2026 at 02:14 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 34.63 |
| High Target | USD 36 |
| Low Target | USD 33 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (ARQT)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.05 |
| Revenue Estimate | $117.29M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.09 vs est -0.06 ▼ miss |
| 2025-12-31 | USD 0.13 vs est 0.09 ▲ beat |
| 2025-09-30 | USD 0.06 vs est -0.09 ▲ beat |
| 2025-06-30 | USD -0.13 vs est -0.16 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financials & Fundamentals (ARQT)
| Total Revenue | $415.62M |
|---|---|
| Revenue Growth (YoY) | +60.10% |
| Gross Margin | +90.94% |
| Operating Margin | -8.62% |
| Profit Margin | -0.57% |
| ROE | -1.43% |
| Debt / Equity | 60.47 |
| Current Ratio | 2.68 |
| Total Cash | $224.00M |
| Total Debt | $114.67M |
| Free Cash Flow | $3.53M |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financial Health Score (ARQT)
Nexqual rates Arcutis Biotherapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:14 UTC.
| Growth | Strong — Revenue +91% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 91%, operating -9% |
| Balance Sheet | Strong — $224M cash vs $115M debt, net cash position |
| Cash Flow | Mixed — FCF $4M, slim 0.9% margin |
| Efficiency | Critical — ROE -1%, ROA 0.5% |
Ownership (ARQT)
| Insider Ownership | +1.76% |
|---|---|
| Institutional Ownership | +109.94% |
| Shares Outstanding | 125.08M |
| Float | 92.59M |
| Short % of Float | +13.84% |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Leadership (ARQT)
Arcutis Biotherapeutics, Inc. is led by Todd Franklin Watanabe M.A. (age 57), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:14 UTC.
| President, CEO & Director | Todd Franklin Watanabe M.A. (age 57) |
|---|---|
| Co-Founder & Director Emeritus | Bhaskar Chaudhuri (age 70) |
| Senior VP & Chief Financial Officer | Latha Vairavan (age 47) |
| Vice President of Compliance & Privacy | Steve Arias |
| Vice President of Marketing | Aleen Hosdaghian |
Major Backers & Investors (ARQT)
Notable institutional backers of Arcutis Biotherapeutics, Inc. include Suvretta Capital Management, LLC, Frazier Life Sciences Management, L.P. , Rubric Capital Management LP, according to Nexqual as of June 10, 2026 at 02:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 9.86% |
| Frazier Life Sciences Management, L.P. | 7.89% |
| Rubric Capital Management LP | 6.61% |
| Polar Capital Holdings PLC | 4.53% |
| Jennison Associates LLC | 3.98% |
| Gilder Gagnon Howe & Co LLC | 3.44% |
| Morgan Stanley | 3.37% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.8% |
| State Street | 8.1% |
| Vanguard Group | 7.69% |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
From Arcutis Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- In November 2025, our supplemental New Drug Application (sNDA) was accepted for filing by the FDA to potentially expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026.
- We believe we have built a leading platform for dermatologic product development and commercialization.
- We believe our management team's experience in developing dermatological drugs, including biologics, will enable us to effectively move ARQ-234 through the development process.
Partnerships
- In July 2018, we executed a licensing agreement with AstraZeneca AB (AstraZeneca) for exclusive worldwide rights to roflumilast as a topical product in humans solely for dermatological indications.
- In August 2023, we entered into a strategic collaboration and licensing agreement (the Huadong Agreement) for topical roflumilast in Greater China and Southeast Asia with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Huadong). a wholly owned subsidiary of Huadong Medicine Co., Ltd.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| CCCC | C4 Therapeutics, Inc. | USD 3.58 | ▼ 7.01% |
| ALXO | ALX Oncology Holdings Inc. | USD 1.55 | ▲ 0.65% |
| TVTX | Travere Therapeutics, Inc. | USD 48.57 | ▲ 6.02% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:14 UTC. This page is informational and not investment advice.